Are you a clinical specialist involved in the diagnosis and management of patients with suspected dementia?
Are you a clinical specialist involved in the diagnosis and management of patients with suspected dementia?
Photo: Designed by Freepik
Published 6 March 2025
Share this article
PREDICTOM is inviting clinical specialists (aka secondary and tertiary care physicians) to complete this short survey. We want to hear about your current clinical practice when managing patients who you suspect have dementia. We also ask some questions about Alzheimer’s disease and mild cognitive impairment.
Your responses will help us develop recommendations for optimising clinical practice guidelines, considering new technologies to support diagnosis and facilitators and barriers to implementation.
Eye-tracking technology is emerging as a promising tool for early detection of cognitive decline. By analyzing involuntary eye movements, researchers can identify subtle cognitive and attentional changes that may accompany the earliest stages of mild cognitive impairment and Alzheimer’s disease — sometimes before these changes are evident on traditional paper-based tests. This article explores the science, clinical applications, and innovations driving this breakthrough.
PREDICTOM clinical study has now been launched. The study is recruiting healthy people who are based in UK, Norway, Spain, Geneva, Germany, France and Brussels. Are you interested in our study? Are you uncertain about the tests involved? Why do we have these tests? Are they able to detect early-signs of dementia?
To take you insde our study, explore the different tests and methods involved, we will publish a series of news articles dedicated to the PREDICTOM clinical study. In the first article of the series, we are presenting the hearing test.
A new publication from PREDICTOM introduces a promising method to dramatically accelerate multi-contrast brain MRI scans, without sacrificing image quality. The technique could pave the way for earlier and more accessible diagnosis of neurodegenerative diseases like Alzheimer’s disease.
